KR20240123837A - 신속한 t 세포 제조 - Google Patents
신속한 t 세포 제조 Download PDFInfo
- Publication number
- KR20240123837A KR20240123837A KR1020247024364A KR20247024364A KR20240123837A KR 20240123837 A KR20240123837 A KR 20240123837A KR 1020247024364 A KR1020247024364 A KR 1020247024364A KR 20247024364 A KR20247024364 A KR 20247024364A KR 20240123837 A KR20240123837 A KR 20240123837A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- cell
- activating
- population
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 184
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 131
- 210000004027 cell Anatomy 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 77
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 65
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 65
- 210000001616 monocyte Anatomy 0.000 claims description 57
- 238000010361 transduction Methods 0.000 claims description 57
- 230000026683 transduction Effects 0.000 claims description 56
- 102000004127 Cytokines Human genes 0.000 claims description 48
- 108090000695 Cytokines Proteins 0.000 claims description 48
- 239000013598 vector Substances 0.000 claims description 42
- 230000003213 activating effect Effects 0.000 claims description 40
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 36
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 36
- 239000011324 bead Substances 0.000 claims description 28
- 230000006044 T cell activation Effects 0.000 claims description 27
- 230000003612 virological effect Effects 0.000 claims description 24
- 102000003812 Interleukin-15 Human genes 0.000 claims description 23
- 108090000172 Interleukin-15 Proteins 0.000 claims description 23
- 108010002586 Interleukin-7 Proteins 0.000 claims description 23
- 239000013612 plasmid Substances 0.000 claims description 22
- 210000005087 mononuclear cell Anatomy 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 19
- 239000013603 viral vector Substances 0.000 claims description 18
- 239000012190 activator Substances 0.000 claims description 17
- 241000713666 Lentivirus Species 0.000 claims description 16
- 108010002350 Interleukin-2 Proteins 0.000 claims description 15
- 102000000588 Interleukin-2 Human genes 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000002617 apheresis Methods 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 10
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 8
- 238000003306 harvesting Methods 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 230000000779 depleting effect Effects 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 3
- 102100030704 Interleukin-21 Human genes 0.000 claims description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 238000001085 differential centrifugation Methods 0.000 claims description 3
- 108010074108 interleukin-21 Proteins 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 abstract description 2
- 239000012642 immune effector Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 239000000047 product Substances 0.000 description 85
- 108020004414 DNA Proteins 0.000 description 59
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 49
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 37
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 36
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 36
- 239000007825 activation reagent Substances 0.000 description 27
- 102000000704 Interleukin-7 Human genes 0.000 description 20
- 238000001994 activation Methods 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 241000700605 Viruses Species 0.000 description 17
- 238000013459 approach Methods 0.000 description 17
- 238000000684 flow cytometry Methods 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000011529 RT qPCR Methods 0.000 description 15
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000002955 isolation Methods 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 230000008901 benefit Effects 0.000 description 9
- 238000012429 release testing Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 241001068263 Replication competent viruses Species 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101001135406 Homo sapiens Polypyrimidine tract-binding protein 2 Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102100033280 Polypyrimidine tract-binding protein 2 Human genes 0.000 description 2
- 229940126530 T cell activator Drugs 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 108010056030 retronectin Proteins 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000034809 Product contamination Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940081858 plasmalyte a Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292843P | 2021-12-22 | 2021-12-22 | |
| US63/292,843 | 2021-12-22 | ||
| PCT/US2022/053815 WO2023122277A2 (en) | 2021-12-22 | 2022-12-22 | Rapid t-cell manufacturing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240123837A true KR20240123837A (ko) | 2024-08-14 |
Family
ID=86903666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247024364A Pending KR20240123837A (ko) | 2021-12-22 | 2022-12-22 | 신속한 t 세포 제조 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250027042A1 (https=) |
| EP (2) | EP4453188A4 (https=) |
| JP (2) | JP2024546145A (https=) |
| KR (1) | KR20240123837A (https=) |
| CN (1) | CN119698465A (https=) |
| AR (2) | AR128077A1 (https=) |
| AU (1) | AU2022422123A1 (https=) |
| CA (1) | CA3239503A1 (https=) |
| CL (1) | CL2024001919A1 (https=) |
| CO (1) | CO2024008914A2 (https=) |
| IL (1) | IL313516A (https=) |
| MX (1) | MX2024007669A (https=) |
| UY (1) | UY40089A (https=) |
| WO (2) | WO2023122277A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024546145A (ja) * | 2021-12-22 | 2024-12-17 | クレ．エーアイ，インク． | 迅速ｔ－細胞製造 |
| WO2025083196A1 (en) | 2023-10-18 | 2025-04-24 | Tq Therapeutics Gmbh | A method of manufacturing a cellular therapy product and respective kits and devices |
| EP4725578A1 (en) | 2024-10-08 | 2026-04-15 | TQ Therapeutics GmbH | Column designs for affinity chromatography |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244806A (en) * | 1985-08-26 | 1993-09-14 | Eli Lilly And Company | DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells |
| CU24649B1 (es) * | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| GB201622044D0 (en) * | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
| CN113840911A (zh) * | 2018-09-02 | 2021-12-24 | 埃克苏马生物技术公司 | 用于在血液中或在富集pbmc中基因修饰淋巴细胞的方法和组合物 |
| JP2024546145A (ja) * | 2021-12-22 | 2024-12-17 | クレ．エーアイ，インク． | 迅速ｔ－細胞製造 |
-
2022
- 2022-12-22 JP JP2024535789A patent/JP2024546145A/ja active Pending
- 2022-12-22 IL IL313516A patent/IL313516A/en unknown
- 2022-12-22 AR ARP220103561A patent/AR128077A1/es unknown
- 2022-12-22 KR KR1020247024364A patent/KR20240123837A/ko active Pending
- 2022-12-22 US US18/714,302 patent/US20250027042A1/en active Pending
- 2022-12-22 CN CN202280085189.1A patent/CN119698465A/zh active Pending
- 2022-12-22 EP EP22912490.4A patent/EP4453188A4/en active Pending
- 2022-12-22 AU AU2022422123A patent/AU2022422123A1/en active Pending
- 2022-12-22 MX MX2024007669A patent/MX2024007669A/es unknown
- 2022-12-22 WO PCT/US2022/053815 patent/WO2023122277A2/en not_active Ceased
- 2022-12-22 UY UY0001040089A patent/UY40089A/es unknown
- 2022-12-22 CA CA3239503A patent/CA3239503A1/en active Pending
-
2023
- 2023-06-19 JP JP2025536953A patent/JP2026501322A/ja active Pending
- 2023-06-19 EP EP23908030.2A patent/EP4638711A1/en active Pending
- 2023-06-19 WO PCT/US2023/025663 patent/WO2024136920A1/en not_active Ceased
- 2023-08-02 AR ARP230102033A patent/AR130098A1/es unknown
-
2024
- 2024-06-21 CL CL2024001919A patent/CL2024001919A1/es unknown
- 2024-07-04 CO CONC2024/0008914A patent/CO2024008914A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR130098A1 (es) | 2024-11-06 |
| WO2024136920A4 (en) | 2025-06-12 |
| JP2024546145A (ja) | 2024-12-17 |
| UY40089A (es) | 2023-07-14 |
| WO2023122277A2 (en) | 2023-06-29 |
| CN119698465A (zh) | 2025-03-25 |
| EP4638711A1 (en) | 2025-10-29 |
| WO2024136920A1 (en) | 2024-06-27 |
| WO2023122277A3 (en) | 2023-08-24 |
| JP2026501322A (ja) | 2026-01-14 |
| AU2022422123A1 (en) | 2024-07-11 |
| EP4453188A4 (en) | 2025-12-03 |
| CO2024008914A2 (es) | 2024-08-08 |
| EP4453188A2 (en) | 2024-10-30 |
| CA3239503A1 (en) | 2023-06-29 |
| IL313516A (en) | 2024-08-01 |
| AR128077A1 (es) | 2024-03-20 |
| MX2024007669A (es) | 2024-07-09 |
| US20250027042A1 (en) | 2025-01-23 |
| CL2024001919A1 (es) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fritsche et al. | Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy | |
| Cheadle et al. | Chimeric antigen receptors for T-cell based therapy | |
| Seay et al. | Expansion of human Tregs from cryopreserved umbilical cord blood for GMP-compliant autologous adoptive cell transfer therapy | |
| EP3134515B1 (en) | Application of induced pluripotent stem cells to generate adoptive cell therapy products | |
| Ciceri et al. | Antitumor effects of HSV-TK–engineered donor lymphocytes after allogeneic stem-cell transplantation | |
| EP4635978A2 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| KR20240123837A (ko) | 신속한 t 세포 제조 | |
| US9670459B2 (en) | Production method for cell populations | |
| EP3619302A1 (en) | Compositions and methods for gene editing in t cells using crispr/cpf1 | |
| Sundarasetty et al. | Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation | |
| Fesnak et al. | Considerations in T cell therapy product development for B cell leukemia and lymphoma immunotherapy | |
| EP4347811A2 (en) | Gene editing in primary immune cells using cell penetrating crispr-cas system | |
| US20260071238A1 (en) | Materials and processes for engineering hypoimmunogenicity | |
| US20250101467A1 (en) | Preparation technique for universal car-t cell, and use of universal car-t cell thereof | |
| Palianina et al. | A method for polyclonal antigen-specific T cell-targeted genome editing (TarGET) for adoptive cell therapy applications | |
| RU2822196C2 (ru) | Способы получения клеток, экспрессирующих химерный антигенный рецептор | |
| Kubik et al. | Manufacturing and clinical applications of non-CAR-T immune effector cells. | |
| HK40014033A (en) | Methods of making and using embryonic mesenchymal progenitor cells | |
| HK1233303B (en) | Application of induced pluripotent stem cells to generate adoptive cell therapy products | |
| HK1233303A1 (en) | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240719 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application |